Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 13, 2022 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Reports Positive Pre-clinical Results for Lead Program in Cancer-Related Cachexia

SOLANA BEACH, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
March 28, 2022 09:25 ET | Source: Artelo Biosciences

Artelo Expands Collaboration with Trinity College Dublin to Investigate Cellular Biology of Fatty Acid Binding Protein (FABP) Inhibition In Cancer

SOLANA BEACH, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
March 22, 2022 09:00 ET | Source: Artelo Biosciences

Artelo Biosciences to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th

SOLANA BEACH, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
March 21, 2022 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Reports Four-Month 2021 Financial Results in Connection with its Amended Fiscal Year End and Provides Business Update

SOLANA BEACH, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
March 02, 2022 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Receives Notice of Allowance for Method-of-Use Patent in the United States for ART12.11, a Proprietary Cocrystal of Cannabidiol

SOLANA BEACH, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
January 12, 2022 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update

Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30, 2021 SOLANA BEACH, Calif.,...
January 11, 2022 08:30 ET | Source: Artelo Biosciences

Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom

SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical...
January 10, 2022 09:00 ET | Source: Artelo Biosciences

Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference

SOLANA BEACH, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling...
November 29, 2021 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update

SOLANA BEACH, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling...
September 08, 2021 08:30 ET | Source: Artelo Biosciences

Artelo Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

SOLANA BEACH, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate endogenous signaling...